Cargando…

Comparison of 3D Conformal Proton Therapy, Intensity-Modulated Proton Therapy, and Intensity-Modulated Photon Therapy for Retroperitoneal Sarcoma

BACKGROUND: External beam radiation therapy (RT) for retroperitoneal sarcoma often requires treatment of large target volumes close to critical normal tissues. Radiation may be limited by adjacent organs at risk (OAR). Intensity-modulated radiation therapy has been shown to improve target coverage a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Christine, Trofimov, Alexei, Adams, Judith, Kung, Jong, Kirsch, David G., Yoon, Sam, Doppke, Karen, Bortfeld, Thomas, Delaney, Thomas F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957461/
https://www.ncbi.nlm.nih.gov/pubmed/35345672
http://dx.doi.org/10.1155/2022/5540615
_version_ 1784676769618460672
author Chung, Christine
Trofimov, Alexei
Adams, Judith
Kung, Jong
Kirsch, David G.
Yoon, Sam
Doppke, Karen
Bortfeld, Thomas
Delaney, Thomas F.
author_facet Chung, Christine
Trofimov, Alexei
Adams, Judith
Kung, Jong
Kirsch, David G.
Yoon, Sam
Doppke, Karen
Bortfeld, Thomas
Delaney, Thomas F.
author_sort Chung, Christine
collection PubMed
description BACKGROUND: External beam radiation therapy (RT) for retroperitoneal sarcoma often requires treatment of large target volumes close to critical normal tissues. Radiation may be limited by adjacent organs at risk (OAR). Intensity-modulated radiation therapy has been shown to improve target coverage and reduce doses to OAR. OBJECTIVES: To compare target coverage and dose to OAR with 3D conformal proton therapy (3D CPT), intensity-modulated proton therapy (IMPT), and intensity-modulated photon therapy (IMXT). METHODS: We performed a comparative study of treatment plans with 3D CPT, IMPT, and IMXT for ten patients with retroperitoneal sarcomas. RT was delivered to 50.4 Gy to the clinical target volume (CTV), the structures considered at risk for microscopic disease. RESULTS: CTVs ranged from 74 to 357 cc (mean 188 cc). Dose conformity was improved with IMPT, while 3D CPT provided better dose homogeneity. Mean dose to the liver, small bowel, and stomach was reduced with IMPT compared with 3D CPT or IMXT. CONCLUSIONS: IMPT, 3D CPT, and IMXT provide excellent target coverage for retroperitoneal sarcomas. OAR dose is lower with IMPT and 3D CPT, and IMPT achieves the closest conformity. These techniques offer the opportunity for further dose escalation to areas with positive margins.
format Online
Article
Text
id pubmed-8957461
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-89574612022-03-27 Comparison of 3D Conformal Proton Therapy, Intensity-Modulated Proton Therapy, and Intensity-Modulated Photon Therapy for Retroperitoneal Sarcoma Chung, Christine Trofimov, Alexei Adams, Judith Kung, Jong Kirsch, David G. Yoon, Sam Doppke, Karen Bortfeld, Thomas Delaney, Thomas F. Sarcoma Research Article BACKGROUND: External beam radiation therapy (RT) for retroperitoneal sarcoma often requires treatment of large target volumes close to critical normal tissues. Radiation may be limited by adjacent organs at risk (OAR). Intensity-modulated radiation therapy has been shown to improve target coverage and reduce doses to OAR. OBJECTIVES: To compare target coverage and dose to OAR with 3D conformal proton therapy (3D CPT), intensity-modulated proton therapy (IMPT), and intensity-modulated photon therapy (IMXT). METHODS: We performed a comparative study of treatment plans with 3D CPT, IMPT, and IMXT for ten patients with retroperitoneal sarcomas. RT was delivered to 50.4 Gy to the clinical target volume (CTV), the structures considered at risk for microscopic disease. RESULTS: CTVs ranged from 74 to 357 cc (mean 188 cc). Dose conformity was improved with IMPT, while 3D CPT provided better dose homogeneity. Mean dose to the liver, small bowel, and stomach was reduced with IMPT compared with 3D CPT or IMXT. CONCLUSIONS: IMPT, 3D CPT, and IMXT provide excellent target coverage for retroperitoneal sarcomas. OAR dose is lower with IMPT and 3D CPT, and IMPT achieves the closest conformity. These techniques offer the opportunity for further dose escalation to areas with positive margins. Hindawi 2022-03-19 /pmc/articles/PMC8957461/ /pubmed/35345672 http://dx.doi.org/10.1155/2022/5540615 Text en Copyright © 2022 Christine Chung et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Chung, Christine
Trofimov, Alexei
Adams, Judith
Kung, Jong
Kirsch, David G.
Yoon, Sam
Doppke, Karen
Bortfeld, Thomas
Delaney, Thomas F.
Comparison of 3D Conformal Proton Therapy, Intensity-Modulated Proton Therapy, and Intensity-Modulated Photon Therapy for Retroperitoneal Sarcoma
title Comparison of 3D Conformal Proton Therapy, Intensity-Modulated Proton Therapy, and Intensity-Modulated Photon Therapy for Retroperitoneal Sarcoma
title_full Comparison of 3D Conformal Proton Therapy, Intensity-Modulated Proton Therapy, and Intensity-Modulated Photon Therapy for Retroperitoneal Sarcoma
title_fullStr Comparison of 3D Conformal Proton Therapy, Intensity-Modulated Proton Therapy, and Intensity-Modulated Photon Therapy for Retroperitoneal Sarcoma
title_full_unstemmed Comparison of 3D Conformal Proton Therapy, Intensity-Modulated Proton Therapy, and Intensity-Modulated Photon Therapy for Retroperitoneal Sarcoma
title_short Comparison of 3D Conformal Proton Therapy, Intensity-Modulated Proton Therapy, and Intensity-Modulated Photon Therapy for Retroperitoneal Sarcoma
title_sort comparison of 3d conformal proton therapy, intensity-modulated proton therapy, and intensity-modulated photon therapy for retroperitoneal sarcoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957461/
https://www.ncbi.nlm.nih.gov/pubmed/35345672
http://dx.doi.org/10.1155/2022/5540615
work_keys_str_mv AT chungchristine comparisonof3dconformalprotontherapyintensitymodulatedprotontherapyandintensitymodulatedphotontherapyforretroperitonealsarcoma
AT trofimovalexei comparisonof3dconformalprotontherapyintensitymodulatedprotontherapyandintensitymodulatedphotontherapyforretroperitonealsarcoma
AT adamsjudith comparisonof3dconformalprotontherapyintensitymodulatedprotontherapyandintensitymodulatedphotontherapyforretroperitonealsarcoma
AT kungjong comparisonof3dconformalprotontherapyintensitymodulatedprotontherapyandintensitymodulatedphotontherapyforretroperitonealsarcoma
AT kirschdavidg comparisonof3dconformalprotontherapyintensitymodulatedprotontherapyandintensitymodulatedphotontherapyforretroperitonealsarcoma
AT yoonsam comparisonof3dconformalprotontherapyintensitymodulatedprotontherapyandintensitymodulatedphotontherapyforretroperitonealsarcoma
AT doppkekaren comparisonof3dconformalprotontherapyintensitymodulatedprotontherapyandintensitymodulatedphotontherapyforretroperitonealsarcoma
AT bortfeldthomas comparisonof3dconformalprotontherapyintensitymodulatedprotontherapyandintensitymodulatedphotontherapyforretroperitonealsarcoma
AT delaneythomasf comparisonof3dconformalprotontherapyintensitymodulatedprotontherapyandintensitymodulatedphotontherapyforretroperitonealsarcoma